BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 26177314)

  • 1. Clinical Implications of Accurate Subtyping of Pituitary Adenomas: Perspectives from the Treating Physician.
    Gomez-Hernandez K; Ezzat S; Asa SL; Mete Ö
    Turk Patoloji Derg; 2015; 31 Suppl 1():4-17. PubMed ID: 26177314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Silent subtype 3 pituitary adenomas are not always silent and represent poorly differentiated monomorphous plurihormonal Pit-1 lineage adenomas.
    Mete O; Gomez-Hernandez K; Kucharczyk W; Ridout R; Zadeh G; Gentili F; Ezzat S; Asa SL
    Mod Pathol; 2016 Feb; 29(2):131-42. PubMed ID: 26743473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry.
    Saeger W; Lüdecke DK; Buchfelder M; Fahlbusch R; Quabbe HJ; Petersenn S
    Eur J Endocrinol; 2007 Feb; 156(2):203-16. PubMed ID: 17287410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-functioning pituitary adenomas with positive immunoreactivity for ACTH behave more aggressively than ACTH immunonegative tumours but do not recur more frequently.
    Bradley KJ; Wass JA; Turner HE
    Clin Endocrinol (Oxf); 2003 Jan; 58(1):59-64. PubMed ID: 12519413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overview of the 2017 WHO Classification of Pituitary Tumors.
    Mete O; Lopes MB
    Endocr Pathol; 2017 Sep; 28(3):228-243. PubMed ID: 28766057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathologic correlates of giant pituitary adenomas.
    Chacko G; Chacko AG; Lombardero M; Mani S; Seshadri MS; Kovacs K; Scheithauer BW
    J Clin Neurosci; 2009 May; 16(5):660-5. PubMed ID: 19285407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic implications of accurate classification of pituitary adenomas.
    Mete O; Asa SL
    Semin Diagn Pathol; 2013 Aug; 30(3):158-64. PubMed ID: 24144285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utility of Pit-1 Immunostaining in Distinguishing Pituitary Adenomas of Primitive Differentiation from Null Cell Adenomas.
    Lee JC; Pekmezci M; Lavezo JL; Vogel H; Katznelson L; Fraenkel M; Harsh G; Dulai M; Perry A; Tihan T
    Endocr Pathol; 2017 Dec; 28(4):287-292. PubMed ID: 28994039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical features of silent corticotroph adenomas.
    Alahmadi H; Lee D; Wilson JR; Hayhurst C; Mete O; Gentili F; Asa SL; Zadeh G
    Acta Neurochir (Wien); 2012 Aug; 154(8):1493-8. PubMed ID: 22619024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synchronous Multiple Pituitary Neuroendocrine Tumors of Different Cell Lineages.
    Mete O; Alshaikh OM; Cintosun A; Ezzat S; Asa SL
    Endocr Pathol; 2018 Dec; 29(4):332-338. PubMed ID: 30215160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. STRESS IN THE CLASSIFICATION OF PITUITARY TUMORS. FOCUS ON AGGRESSIVE PITUITARY ADENOMAS.
    Kovács K; Rotondo F; Horváth E; Syro LV
    Ideggyogy Sz; 2014 Mar; 67(3-4):126-7. PubMed ID: 26118256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A study of the correlation between morphological findings and biological activities in clinically nonfunctioning pituitary adenomas.
    Yamada S; Ohyama K; Taguchi M; Takeshita A; Morita K; Takano K; Sano T
    Neurosurgery; 2007 Sep; 61(3):580-4; discussion 584-5. PubMed ID: 17881972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Impact of the Current WHO Classification of Pituitary Adenomas.
    Saeger W; Honegger J; Theodoropoulou M; Knappe UJ; Schöfl C; Petersenn S; Buslei R
    Endocr Pathol; 2016 Jun; 27(2):104-14. PubMed ID: 26860936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunocytochemical localization of macrophage migration inhibitory factor in human hypophysis and pituitary adenomas.
    Tampanaru-Sarmesiu A; Stefaneanu L; Thapar K; Kovacs K; Donnelly T; Metz CN; Bucala R
    Arch Pathol Lab Med; 1997 Apr; 121(4):404-10. PubMed ID: 9140312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular, functional, and histopathological classification of the pituitary neuroendocrine neoplasms.
    Inomoto C; Tahara S; Oyama K; Kimura M; Matsuno A; Teramoto A; Osamura RY
    Brain Tumor Pathol; 2021 Jul; 38(3):183-188. PubMed ID: 34269950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Invasive pituitary adenomas: significance of proliferation parameters.
    Amar AP; Hinton DR; Krieger MD; Weiss MH
    Pituitary; 1999 Aug; 2(2):117-22. PubMed ID: 11081161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A clinicomorphological study of pituitary tumors associated with the clinical syndrome of acromegaly.
    Andreeva M; Georgiev T; Bosadjieva E; Karagiosov L; Karagiosov K; Tomova A; Matrosov P; Kirilov G; Diankov L; Christova T
    Exp Clin Endocrinol; 1991; 98(3):223-7. PubMed ID: 1778242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endocrine and morphological study of a clinically silent somatotroph adenoma of the human pituitary.
    Yamada S; Sano T; Stefaneanu L; Kovacs K; Aiba T; Sawano S; Shishiba Y
    J Clin Endocrinol Metab; 1993 Feb; 76(2):352-6. PubMed ID: 8432778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current pathological classification of pituitary adenomas.
    Saeger W
    Acta Neurochir Suppl; 1996; 65():1-3. PubMed ID: 8738481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New WHO classification of pituitary adenomas (4th edition): assessment of pituitary transcription factors and the prognostic histological factors.
    Nishioka H; Inoshita N
    Brain Tumor Pathol; 2018 Apr; 35(2):57-61. PubMed ID: 29318396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.